Assembly Biosciences, Inc. Payments to Acquire Marketable Securities
Assembly Biosciences, Inc. (ASMB) reported Payments to Acquire Marketable Securities of $93.67 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2019-08-05
- Assembly Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2019-06-30 was $44.64M, a 133.27% increase year-over-year.
- Assembly Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2019-03-31 was $49.03M, a 276.23% increase year-over-year.
- Assembly Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2018-12-31 was $68.91M, a 739.19% increase year-over-year.
- Assembly Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2018-09-30 was $82.86M, a 1015.06% increase year-over-year.
- Assembly Biosciences, Inc. payments to acquire marketable securities for fiscal 2018 was $183.94M, a 281.35% increase from fiscal 2017.
- Assembly Biosciences, Inc. payments to acquire marketable securities for fiscal 2017 was $48.23M, a 506.64% increase from fiscal 2016.
- Assembly Biosciences, Inc. payments to acquire marketable securities for fiscal 2016 was $7.95M, a 88.61% decline from fiscal 2015.
- Assembly Biosciences, Inc. payments to acquire marketable securities for fiscal 2015 was $69.78M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 3 month as first filed | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2019-06-30 | $44.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $93.67M 10-Q · filed 2019-08-05 | $162.58M derived: sum of 3 quarters · filed 2019-08-05 | $245.44M derived: sum of 4 quarters · filed 2019-08-05 | |||
| 2019-03-31 | $49.03M 10-Q · filed 2019-05-09 | $117.94M derived: sum of 2 quarters · filed 2019-05-09 | $200.80M derived: sum of 3 quarters · filed 2019-05-09 | $219.94M derived: sum of 4 quarters · filed 2019-08-05 | |||
| 2018-12-31 | $68.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $151.77M derived: sum of 2 quarters · filed 2019-02-28 | $170.91M derived: sum of 3 quarters · filed 2019-08-05 | $183.94M 10-K · filed 2019-02-28 | |||
| 2018-09-30 | $82.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $102.00M derived: sum of 2 quarters · filed 2019-08-05 | $115.03M 10-Q · filed 2018-11-08 | $123.24M derived: sum of 4 quarters · filed 2019-08-05 | |||
| 2018-06-30 | $19.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $32.17M 10-Q · filed 2019-08-05 | $32.17M 10-Q · filed 2018-08-08 | $40.38M derived: sum of 3 quarters · filed 2019-08-05 | $47.81M derived: sum of 4 quarters · filed 2019-08-05 | ||
| 2018-03-31 | $13.03M 10-Q · filed 2019-05-09 | $13.03M 10-Q · filed 2018-05-07 | $21.24M derived: sum of 2 quarters · filed 2019-05-09 | $28.67M derived: sum of 3 quarters · filed 2019-05-09 | $61.27M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $15.64M derived: sum of 2 quarters · filed 2019-02-28 | $48.23M derived: sum of 3 quarters · filed 2019-02-28 | $48.23M 10-K · filed 2019-02-28 | $48.23M 10-K · filed 2018-03-08 | ||
| 2017-09-30 | $7.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $40.02M derived: sum of 2 quarters · filed 2018-11-08 | $40.02M 10-Q · filed 2018-11-08 | $40.02M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-06-30 | $32.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $32.59M 10-Q · filed 2018-08-08 | $32.59M derived: sum of 3 quarters · filed 2019-02-28 | $32.59M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-07 | -$256.00 derived: sum of 2 quarters · filed 2019-02-28 | -$257.00 derived: sum of 3 quarters · filed 2019-02-28 | -$257.00 derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2016-12-31 | -$256.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$257.00 derived: sum of 2 quarters · filed 2019-02-28 | -$257.00 derived: sum of 3 quarters · filed 2019-02-28 | $7.95M 10-K · filed 2019-02-28 | $7.95M 10-K · filed 2017-03-02 | ||
| 2016-09-30 | -$1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$1.00 derived: sum of 2 quarters · filed 2017-11-01 | $7.95M 10-Q · filed 2017-11-01 | $14.06M derived: sum of 4 quarters · filed 2018-03-08 | |||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $7.95M 10-Q · filed 2017-08-09 | $14.06M derived: sum of 3 quarters · filed 2018-03-08 | $28.95M derived: sum of 4 quarters · filed 2018-03-08 | |||
| 2016-03-31 | $7.95M 10-Q · filed 2017-05-08 | $14.06M derived: sum of 2 quarters · filed 2018-03-08 | $28.95M derived: sum of 3 quarters · filed 2018-03-08 | $77.73M derived: sum of 4 quarters · filed 2018-03-08 | |||
| 2015-12-31 | $6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $21.00M derived: sum of 2 quarters · filed 2018-03-08 | $69.78M derived: sum of 3 quarters · filed 2018-03-08 | $69.78M 10-K · filed 2018-03-08 | |||
| 2015-09-30 | $14.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $63.67M derived: sum of 2 quarters · filed 2016-11-09 | $63.67M 10-Q · filed 2016-11-09 | $63.67M derived: sum of 4 quarters · filed 2017-03-02 | |||
| 2015-06-30 | $48.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $48.78M 10-Q · filed 2016-08-09 | $48.78M derived: sum of 3 quarters · filed 2017-03-02 | $48.78M derived: sum of 4 quarters · filed 2017-03-02 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-10 | $0.00 derived: sum of 2 quarters · filed 2017-03-02 | $0.00 derived: sum of 3 quarters · filed 2017-03-02 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $0.00 derived: sum of 2 quarters · filed 2017-03-02 | $0.00 10-K · filed 2017-03-02 | ||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 | |||||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |